I have been the Chief Medical Officer at ESSA Pharma since July 2019.

Previously, I was the Chief Medical Officer of NanoString Inc. from July 2015 to June 2019, where I focused on the development of translational and diagnostic multi-plexed assays for the characterization and measurement of immune response/resistance mechanisms.

Prior to joining NanoString, I served as the Chief Medical Officer at Cleave Biosciences, Inc., and before that, I was the Chief Medical Officer and Chief Operations Officer at Nodality, Inc. There, I built and led the R&D group while providing the overall clinical vision for the organization. Between 1998 and 2008, I held various management positions at Amgen, Biogen Idec, and SmithKline Beecham Pharmaceuticals, where I helped advance several oncology drugs through late-stage development and FDA approvals.

Early in my career, I spent 12 years researching tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center affiliated with the University of Pennsylvania.

I am also a member of several professional and scientific societies, including ASCO, ESMO, ASH, EHA, AACR, and SITC. Within SITC, I co-chair the SITC Industry Committee, serve as an Associate Editor for the Biomarker section of JITC, and actively participate in the SITC Biomarker Working Group.

Throughout my career, I have authored over 140 publications.

I received my MD summa cum laude, a Board Certification in Oncology, and a PhD in Tumor Immunology from the University of Turin.